Program Sponsors Organising committee Back to MiM2017




Program
DAY 1 - Thursday 1st October
08:30 - 09:15 Registration
09:15 - 09:30 Welcome and Housekeeping
09:30 - 10:30 Plenary Session
Sponsored by Medicines for Malaria Venture
Chairs: Teresa Carvalho and Jack Richards
Drug Disposition: A Key Component of Antimalarial Drug Discovery
Professor Susan Charman, MIPS
10:30 - 11:00 Morning tea
Sponsored by Sigma Aldrich
11:00 - 12:30 Session 1: Molecular and Cellular Parasitology
Sponsored by Malaria Journal
Chairs: Susann Herrmann and Charlie Jennison
T1Essential role of SPECT1 and SPECT2 in establishing Plasmodium falciparum liver stage malaria
Annie Yang, The Walter and Eliza Hall Institute
T2Alternative splicing in Apicomplexa is widespread, and its perturbation inhibits Plasmodium life-cycle progression
Lee Yeoh, Bio21
T3Microtubule associated protein SPM3 shows dynamic repositioning during cytokinesis and is required for nascent daughter formation
Nadira Samad, Bio21
T4The lever arm of Apicomplexan parasites: How tight is their grip on human and agricultural disease?
Melanie Williams, The Walter and Eliza Hall Institute
T5Proteomic mapping of mitochondrion and apicoplast in Toxoplasma gondii
Azadeh Seidi, Australian National University
12:30 - 14:00 Lunch & Poster Session (odd numbers)
14:00 - 15:45 Session 2: Immunology
Chairs: Herbert Opi and Vashti Irani
T6Understanding the early events in the initiation of immune responses to blood stage Plasmodium infection
Simon Apte, QIMR Berghofer Medical Research Institute
T7Inflammatory monocyte- and neutrophil-derived CXCL10 impairs efficient control of blood-stage malaria infection and promotes severe disease
Lisa Ioannidis, The Walter and Eliza Hall Institute
T8Surviving a Hostile Environment: Plasmodium falciparum complement evasion strategies
Alexander Kennedy, The Walter and Eliza Hall Institute
T9The Dose Dictates the Poison: Dendritic Cell Responses to the Malaria Parasite Plasmodium falciparum
Xi Zen Yap, Burnet Institute
T10Merozoite surface antigens of malaria are effective vaccine antigens to stimulate antibodies promoting opsonic phagocytosis
Gaoqian Feng, Burnet Institute
T11Antibodies and pre-erythrocytic immunity to malaria
Liriye Kurtovic, Burnet Institute
15:45 - 16:15 Afternoon tea
16:15 - 17:30 Session 3: Malaria in pregnancy and vaccines
Chairs: Elizabeth Aitken and Madi Nije
T12Chondroitin sulphate A modulates the monocyte response to Plasmodium falciparum-infected erythrocytes and pathogen products
Louise Randall, The University of Melbourne
T13Antenatal malaria screening reduces the effect of Plasmodium falciparum infection on preterm birth
Kerryn Moore, The University of Melbourne
T14Influence of maternal nutrient supplementation on malaria antibody immunity during pregnancy and infancy
Upeksha Chandrasiri, Peter Doherty Institute
T15Mapping epitopes within intrinsically disordered proteins of Plasmodium falciparum using computational approaches: implications for immunity and vaccines
Andrew Guy, Burnet Institute
18:00 Conference dinner at The Racecourse Hotel
Sponsored by the Australian Society for Parasitology
DAY 2 - Friday 2nd October
09:00 - 10:45 Session 4: Host-parasite interactions
Sponsored by the School of Medicine, Deakin University
Chairs: Dean Goodman and Stanley Xie
T16The repeat region of ring exported protein 1 maintains Maurer,s cleft architecture and efficient virulence protein trafficking in Plasmodium falciparum
Emma McHugh, Bio21
T17The human kinase PAK is essential for Plasmodium falciparum blood stages and shows an unexpected localisation in infected erythrocytes
Jack Williamson, Monash University
T18Plasmodium falciparum specific exported chaperone Hsp70-x is required for efficient protein export
Sarah Charnaud, Burnet Institute
T19Dissection of PTEX88, a component of the malaria protein export machinery
Scott Chisholm, Deakin University
T20An exported FIKK kinase (FIKK9.4) involved in the phosphorylation of Plasmodium falciparum antigen 332
Ghizal Siddiqui, Monash University
T21Investigation of the export pathway of Plasmodium parasites utilising small molecule inhibitors of plasmepsin V
Michelle Gazdik, The Walter and Eliza Hall Institute
10:45 - 11:15 Morning tea
11:15 - 12:45 Session 5: Plasmodium vivax
Chairs: Jakub Gruszczyk and Andrea Waltman
T22Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo
Adeshina Adekunle, Kirby Institute
T23The transcriptome of the Plasmodium vivax gametocytes and blood-stages using classical and single-cell RNAseq
Cristian Koepfli, The Walter and Eliza Hall Institute
T24Antibody responses to Plasmodium falciparum and P. vivax and prospective risk of Plasmodium infection postpartum
Alistair McLean, Burnet Institute
T25The development and optimisation of a new G6PD deficiency screening assay for safe Plasmodium vivax malaria drug treatment
James O,Donnell, Burnet Institute
T26Acquisition and longevity of antibodies to Plasmodium vivax pre-erythrocytic antigens in Western Thailand
Rhea Longley, The Walter and Eliza Hall Institute
12:45 - 14:15 Lunch and Poster Session II (even numbers)
14:15 - 15:45 Session 6: Drug resistance and discovery
Sponsored by Malaria Journal
Chairs: Danny Wilson and Jeff Seow
T27Molecular markers of Plasmodium falciparum drug resistance from a high transmission setting in Bongo District, Ghana
Charles Narh, Bio21
T28Changes in malaria transmission and immunity and the emergence of artemisinin resistance in Thailand from 2001-2011
Ricardo Ataide, Burnet Institute
T29A randomized open-label clinical trial of artesunate-mefloquine versus chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial)
Matthew Grigg, Menzies School of Health Research
T30Repurposing cancer drugs inhibiting kinases - a new perspective for antimalarial drug discovery?
Simona John von Freyend, Monash University
T31Dihydroartemisinin induces stress pathways in the malaria parasite Plasmodium falciparum
Jess Bridgford, Bio21
15:45 - 16:15 Afternoon tea
16:15 - 17:30 Session 7: Epidemiology
Chairs: Abby Harrison and Camila Franca
T32Var gene diversity of Plasmodium falciparum clinical isolates among six sentinel health sites across Uganda
Shazia Ruybal-Pesantez, Bio21
T33Rising incidence of knowlesi malaria in Sabah, Malaysia, but falling notification-fatality rate in adults with use of intravenous artesunate, and absence of P. knowlesi deaths in children
Bridget Barber, Menzies School of Health Research
T34Using molecular epidemiology to gain insight into the differential epidemiology of Plasmodium falciparum and Plasmodium vivax in the Solomon Islands
Yi Wan Quah, The Walter and Eliza Hall Institute
T35Naturally Acquired Immune Response to the ICAM1 binding PfEMP1 Domain DBL2BPF11_0521 is associated with reduced risk of high density P. falciparum malaria in young Papua New Guinean Children
Sofonias Tessema, The Walter and Eliza Hall Institute
17:30 - 18:00 Awards Ceremony and Closing remarks





Our invited speaker, Professor Susan Charman

Susan Charman is Director of the Centre for Drug Candidate Optimisation, and Professor at the Monash Institute of Pharmaceutical Sciences. She completed her PhD in pharmaceutical science in the US and worked for two years in the pharmaceutical industry before moving to Monash University. She currently leads a team of 20 scientists that undertake ADME-informed drug candidate optimisation in collaboration with drug discovery chemists and biologists to enhance and accelerate drug candidate design and progression. She has established a successful model for conducting collaborative, translational research within a university environment, and her group has contributed to programs that have progressed 22 new drug candidates into clinical trials. She is particularly interested in the lead optimisation of novel drug candidates for neglected and tropical diseases and has contributed to projects resulting in one approved antimalarial, three antimalarial drug candidates currently in clinical development and four in preclinical development. She has attracted significant funding from industry and competitive grants, has published over 130 peer-reviewed manuscripts, and is co-inventor on 7 patents.